title: [Long-term efficacy of chemotherapy for unresectable gastric cancer with multiple bone metastases-a case report].
abstract: A 49-year-old man was admitted to our hospital with back pain, appetite loss, and body weight loss in January 2009. Gastroduodenal endoscopy, abdominal computed tomography( CT), and magnetic resonance imaging( MRI) revealed type 4 advanced gastric cancer( signet-ring cell carcinoma) with multiple lymph node( No. 16 LNs), right adrenal gland, and multiple bone metastases. Between February 2009 and April 2011, 20 courses of S-1( 80 mg/m2) plus CDDP( 60 mg/m2) and zoledronic acid hydrate (4 mg/body) were administrated. Since May 2011, S-1 (70 mg/m2) and zoledronic acid hydrate( 4 mg/body) have been continued. The lymph node and adrenal gland metastases showed a complete response( CR), and the gastric tumor showed a partial response; however, the bone metastases did not show CR or progressive disease (PD) for 4 years after initiation of therapy. Chemotherapy with zoledronic acid hydrate is considered as a useful therapeutic option for advanced unresectable gastric cancer with multiple bone metastases.
authors.affiliation: Dept. of Surgery, Sakai City Hospital.
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Kimura
authors.forename: Tomono
authors.initials: T
authors.lastname: Kawase
authors.forename: Ryohei
authors.initials: R
authors.lastname: Kawabata
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Imamura
authors.forename: Ken
authors.initials: K
authors.lastname: Nakata
authors.forename: Tameyoshi
authors.initials: T
authors.lastname: Yamamoto
authors.forename: Shunji
authors.initials: S
authors.lastname: Kamigaki
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Oda
authors.forename: Satoru
authors.initials: S
authors.lastname: Munakata
authors.forename: Mutsumi
authors.initials: M
authors.lastname: Fukunaga
authors.forename: Hiroki
authors.initials: H
authors.lastname: Ohzato
mesh_terms: D000310:Adrenal Gland Neoplasms / Q000188:drug therapy / Q000556:secondary; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D006801:Humans; D008297:Male; D008875:Middle Aged; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013997:Time Factors